However, a study that evaluated the prognostic role of multiple biomarkers in HCC patients treated with sorafenib showed that baseline IL-8 values failed to detect treatment benefit (Miyahara et al. 2011). The gene discussed is CXCL8; the disease is hepatocellular carcinoma.